SCHEDULE: Deerfield Boosts Larimar Therapeutics Stake to 34.41%

Deerfield Management Company and its affiliated funds increased their beneficial ownership in Larimar Therapeutics, Inc. to 34.41% through a $25 million share purchase in a recent offering.

Summary

• Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Healthcare Innovations Fund, L.P., and Deerfield Partners, L.P. collectively purchased 5,000,000 shares of Larimar Therapeutics, Inc. common stock.
• The shares were acquired at a price of $5.00 per share, totaling an aggregate purchase price of $25,000,000.
• The acquisition was part of an underwritten offering conducted by Larimar Therapeutics, Inc. on February 27, 2026.
• Following these transactions, Deerfield Management Company, L.P. and James E. Flynn beneficially own 35,667,474 shares, representing 34.41% of Larimar Therapeutics' outstanding common stock.
• The total outstanding common stock, including shares issued in the February 2026 Offering, is 103,590,392 shares.
• The beneficial ownership includes 60,500 shares issuable upon exercise of fully vested options held by Jonathan Leff, an employee of Deerfield Management Company, L.P., for the benefit and direction of Deerfield Management Company, L.P.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant institutional investor has increased its stake, indicating continued belief in the company's value, despite the implied dilution from the offering.

Positives

• A significant institutional investor, Deerfield Management, has increased its stake, signaling continued confidence in Larimar Therapeutics' long-term prospects.
• The investment of $25 million by Deerfield entities provides capital to Larimar Therapeutics through the underwritten offering.

Future Outlook

No explicit forward-looking statements or guidance regarding Larimar Therapeutics' future performance or strategic direction are provided by the reporting persons in this filing.

Industry Context

StockSavvy.ai notes that increased institutional ownership, especially from a specialized healthcare investor like Deerfield Management, often signals confidence in a biotechnology company's long-term prospects and pipeline. This significant investment could attract further investor interest and potentially stabilize the stock, particularly following a capital raise.

Stakeholder Impact

• Shareholders: The capital raise through the underwritten offering results in dilution of existing shareholders' ownership percentage. However, the increased stake by a prominent institutional investor like Deerfield Management may be viewed as a positive signal of confidence in the company's future.
• Company: Larimar Therapeutics, Inc. has successfully raised $25 million in capital through the underwritten offering, which can be used to fund operations, research, and development.

Key Dates

Recommendation

The substantial increase in Deerfield Management's stake, reaching over 34% of Larimar Therapeutics, signals strong conviction from a sophisticated healthcare investor. This commitment, demonstrated by a $25 million investment in a recent offering, suggests a belief in the company's long-term potential. However, without details on the company's operational performance or the specific use of proceeds from the offering, a 'hold' recommendation is prudent, acknowledging the positive investor confidence while awaiting further fundamental updates.

Keywords

Larimar Therapeutics, Deerfield Management, Schedule 13D, Beneficial Ownership, Equity Investment, Biotechnology, Pharmaceuticals, LMRK, Institutional Investor, Capital Raise